FIELD: medicine.
SUBSTANCE: method of augmentation of duration of action of physiologically active polypeptide in vivo is described. Physiologically active polypeptide is conjugated with Fc fragment of immunoglobulin by means of PEG. Invention use, in comparison with native physiologically active polypeptide, provides the raised physiological activity in vivo designs and-or augmentation of time of a semilife in Serum of physiologically active polypeptide with the minimum risk of induction of undesirable immune responses.
EFFECT: possibility of application of bond at manufacturing of various polypeptides medicinal preparations of the prolonged action.
11 cl, 18 dwg, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PROTEIN COMPLEX, OBTAINED BY USING FRAGMENT OF IMMUNOGLOBULIN, AND METHOD OF SUCH COMPLEX OBTAINING | 2004 |
|
RU2356909C2 |
| INSULINOTROPIC COMPLEX IN WHICH IMMUNOGLOBULIN FRAGMENT IS USED | 2008 |
|
RU2436589C2 |
| LIQUID COMPOSITION OF LONG-ACTING ALPHA INTERFERON CONJUGATE | 2011 |
|
RU2613905C2 |
| POLYPEPTIDE COMPLEX CONTAINING NON-PEPTIDYL POLYMER, HAVING THREE FUNCTIONAL ENDS | 2009 |
|
RU2483081C2 |
| METHOD OF MASS PRODUCTION OF Fc REGION OF IMMUNOGLOBULIN WITH REMOTE INITIAL METHIONINE RESIDUES | 2006 |
|
RU2428430C2 |
| IMPROVED METHOD FOR PHYSIOLOGICALLY ACTIVE POLYPEPTIDE CONJUGATE PRODUCTION | 2013 |
|
RU2639256C2 |
| NOVEL INSULIN ANALOGUE AND USE THEREOF | 2014 |
|
RU2676729C2 |
| PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT COMPRISING INTERFERON-ALPHA CONJUGATE | 2012 |
|
RU2622077C2 |
| METHOD FOR PRODUCING PHYSIOLOGICALLY ACTIVE POLYPEPTIDE COMPLEX | 2012 |
|
RU2624129C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING OBESITY-RELATED DISEASES CONTAINING INSULINOTROPIC PEPTIDE CONJUGATE | 2008 |
|
RU2446816C2 |
